Perspective Therapeutics Highlights Progress in Radiopharmaceutical Pipeline

Perspective Therapeutics ( (CATX) ) has provided an update.

On February 2, 2026, Perspective Therapeutics posted an investor presentation outlining progress across its pipeline of 212Pb-based radiopharmaceutical therapies and its broader strategy in oncology. The company highlighted ongoing Phase 1/2a clinical trials for three wholly owned candidates: VMT-α-NET for SSTR2-positive neuroendocrine tumors, VMT01 for melanoma, and PSV359 targeting FAP-α in advanced solid tumors, noting compelling anti-tumor activity, durable disease control, and favorable tolerability profiles to date. The presentation emphasized the potential first-in-class positioning of these agents, the optimization of targeted delivery through imaging and proprietary chelation technology, and the company’s secured clinical supply and scaling manufacturing infrastructure, with Phase 1/2 data expected across all three clinical programs in 2026—developments that underscore Perspective’s bid to strengthen its competitive position in the growing radiopharmaceutical market and its prospects for future registration-directed studies.

The most recent analyst rating on (CATX) stock is a Buy with a $4.50 price target. To see the full list of analyst forecasts on Perspective Therapeutics stock, see the CATX Stock Forecast page.

Spark’s Take on CATX Stock

According to Spark, TipRanks’ AI Analyst, CATX is a Neutral.

The score is held back primarily by very weak financial performance (large losses and significant cash burn despite low leverage). Technicals are constructive with the stock trading above major moving averages, but an overbought RSI raises near-term risk. Corporate updates add upside optionality via encouraging early clinical momentum, while valuation remains constrained by ongoing losses and no dividend support.

To see Spark’s full report on CATX stock, click here.

More about Perspective Therapeutics

Perspective Therapeutics operates in the oncology radiopharmaceuticals industry, developing next-generation targeted radioligand therapies based on lead-212 (212Pb) for solid tumors. The company leverages a proprietary radioligand platform and Pb-based chelator technology, with end-to-end manufacturing capabilities and a strong intellectual property portfolio covering the radiopharmaceutical value chain, and is focused on large, unmet-need markets such as neuroendocrine tumors, melanoma, and other solid tumors.

Average Trading Volume: 2,933,312

Technical Sentiment Signal: Hold

Current Market Cap: $281.7M

For an in-depth examination of CATX stock, go to TipRanks’ Overview page.